Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]Camizestrant in Healthy Post-Menopausal Women
NCT05364255Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camizestrant in estrogen receptor-positive breast cancer (ER+), sponsored by AstraZeneca. Primary endpoints: Cumulative amount of AZD9833 excreted, Cumulative percentage of AZD9833 excreted and 3 more. Started May 2022; status: completed.
02
Drugs
camizestrant
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT05364255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364255.